Advancing Immuno-Oncology Therapies in the Fight against Cancer

Our broad immuno-oncology (IO) pipeline targets high unmet medical needs in oncology, with a special emphasis on those patients with solid tumors who respond poorly to PD-1 inhibitors. Our cancer therapy pipeline includes unique investigational therapies, bespoke IO discovery partnerships and IO target licensing. We are focused on advancing IO therapies, and re-engaging the body's immune system, in the fight against cancer, and to providing, in the foreseeable future, targeted treatment strategies to patients most in need, including those who have failed to respond to conventional cancer treatments.

​

Program	Program Summary	Indications	Molecule Class
OBT076^	OBT076 is a CD205-directed ADC, in CD205+ve, and HER2-ve metastatic breast cancer and recurrent and/or metastatic CD205+ve solid tumors currently in a multi-centre Phase I US-based clinical trial. Click here for Clinical Trials information	​Metastatic breast cancer and recurrent and/or metastatic solid tumors (gastric, ovarian, lung)	ADC
OX003R	OX003R (click here for accompanying audio) is a unique immuno-modulatory receptor highly expressed in tumor infiltrating lymphocytes (TILs) of ten different solid tumor types and in activated T cells. OBT has developed anti-OX003 as a humanized first-in-class antibody directed against the human extracellular domain of OX003R antigen. It shows a strong agonistic effect on activated CD8+ T cells promoting their proliferation, cytokine secretion, and cytolytic ability, and suppresses Treg function. The antitumor activity of OX003 is demonstrated by enhancement of cytotoxicity of tumor cells (including HCT116, MDA-MB-231, and BT474). OX003 antibody therapy as a single agent will be investigated in a Phase I clinical study in patients across a range of solid tumors, especially in human cancers that show the presence of TILs, including small cell lung cancer, non-small cell lung cancer, skin cancer, breast cancer.	Solid tumors	IO mAB
OX001R	​Our discovery of a novel T cell modulatory axis (OX001R/L) involved in cancer immune escape independent of the PD1/PDL1 axis has yielded a therapeutic antibody candidate, OX001R, that displays efficacy at least equipotent to Pemrolizumab in a humanized lung cancer model.  OX001R is now entering IND enabling studies.	​Solid tumors	IO mAB
OX001R/ PDL1	T cell engagement of tumor cells in vitro and in patients leads to down regulation of the OX001R ligand – and upregulation of PDL1. We have developed a bispecific molecule combining our OX001R agonist (supplementing the missing ligand) with a PDL1 antagonist.	NSCLC, Breast, Ovarian, HCC, Bladder, Melanoma	​IO/ bispecific
OX003R/ PDL1	Bispecific combining the novel immune-checkpoint regulator, OX003R with a PDL1 antibody in a single molecule.	Solid tumors	IO/ bispecific
ADC I	An ADC specifically targeting ‘cold’ tumors that cannot be treated with check point inhibitors.	“Cold” and solid tumors	ADC
​ADC II, III	Novel ADC targets overexpressed in multiple solid tumors with strong cancer biology.	Solid tumors	ADC
OBT620^^	A DLL3/CD3 bispecific molecule to treat patients with small cell lung cancer and other neuroendocrine tumors that are positive for DLL3. Currently in phase I clinical trial.	SCLC and neuroendocrine tumors	​CD3 bispecific
​OBT624^^	An undisclosed bispecific molecule.	Undisclosed	​CD3 bispecific
Up to 5 Programs^^	OBT and Boehringer Ingelheim (BI) will collaborate to discover and validate novel selective tumor targets for BI’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by OBTs OGAP® discovery platform.	Solid tumors	​Undisclosed
Up to 5 Programs^^^	​Through this collaboration, OBT will validate five novel oncology drug targets, previously identified using OBT’s OGAP® discovery platform, and generate antibodies against these. Kite and Gilead will have the exclusive right to develop and commercialize therapies based on these targets or antibodies.	Hematological and solid tumors	​CAR-T therapy

 ^Partnered with Menarini
^^Partnered with Boehringer Ingelheim
^^^Partnered with Kite, a Gilead Company

ADC: Antibody Drug Conjugate
IO: Immuno-oncology
mAb: Monoclonal Antibody
CAR-T therapy: Chimeric antigen receptor T cell therapy